Anti-Human CTLA-4 (Ipilimumab) - Fc Muted HRP

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Human

Expression Host

HEK-293

FC Effector Activity

Muted

Immunogen

Human CTLA-4

Product Concentration

0.5 mg/ml

Formulation

This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)

Storage and Handling

This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.

Regulatory Status

Research Use Only (RUO). Non-Therapeutic.

Country of Origin

USA

Shipping

Next Day 2-8°C

RRID

AB_2893924

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA

Additional Reported Applications For Relevant Conjugates ?

B
CyTOF®

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.

Antigen Distribution

CTLA4 is constitutively expressed in regulatory T cells.

Background

Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body’s ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body’s own immune response against cancer cells.”² Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.¹ This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

Antigen Details

Protein

CTLA-4

PubMed

CTLA-4

NCBI Gene Bank ID

1493

UniProt.org

Information on Uniprot.org

Research Area

Immunology

.

Inhibitory Molecules

References & Citations

1. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33.

2. Soo, RA. et al. (2017) Lancet Oncol. 18(12):e731-e741.

3. Lipson, EJ. and Drake, CG. (2011) Clin Cancer Res 17(22):6958-62.

Technical Protocols